Sitka Biopharma is a Canadian-Controlled Private Corporation (CCPC) developing a breakthrough polymeric nanoparticle drug delivery platform for localized administration. A significant seed investment by Quark Venture is enabling Sitka to complete preclinical development and to advance their lead program into clinical trials for the treatment of bladder cancer.
Sitka Biopharma’s patented polymeric nanoparticle-based platform technology has the potential to address drug absorption challenges in a variety of indications. We welcome opportunities to collaborate with biopharmaceutical companies that wish to take advantage of our HPG nanoparticle technology.
If you are interested in exploring investment or partnership opportunities with Sitka Biopharma, please contact:
Michael Parr, PhD
President & CSO
Sitka Biopharma is a spin-out from The Centre for Drug Research and Development (CDRD). The technology originated as a collaboration between CDRD and the laboratories of Dr. Helen Burt and Dr. Don Brooks at the University of British Columbia and Dr. Martin Gleave at the Vancouver Prostate Centre (VPC).